

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark one):

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 1997

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 333-18565

EMCORE CORPORATION
(Exact name of Registrant as specified in its charter)

NEW JERSEY
(State or other jurisdiction of incorporation or organization)

22-2746503
(IRS Employer Identification No.)

394 ELIZABETH AVENUE
SOMERSET, NJ 08873
(Address of principal executive offices) (zip code)

(908) 271-9090
(Registrant's telephone number, including area code)

NO CHANGE
(Former name or former address, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes: X No:

As of July 21, 1997, there were 5,921,190 shares of the registrant's common stock outstanding.

This quarterly report of Form 10-Q contains 17 pages, of which this is page 1.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

<TABLE>

EMCORE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(AMOUNTS IN THOUSANDS EXCEPT PER SHARE DATA)
(UNAUDITED)

	THREE MONTHS ENDED		NINE MONTHS ENDED	
	JUNE 30,		JUNE 30,	
<S>	1997	1996	1997	1996
	<C>	<C>	<C>	<C>
Revenue	\$14,106	\$7,726	\$35,626	\$17,995
Cost of sales	8,208	5,495	23,787	12,317
Gross profit	\$5,898	\$2,231	\$11,839	\$5,678
Operating expenses:				
Selling, general and administrative	2,573	1,901	6,715	4,956
Research and development	2,418	1,708	6,655	3,697
Total operating expenses	\$4,991	\$3,609	\$13,370	\$8,653
Operating income (loss)	\$907	(\$1,378)	(\$1,531)	(\$2,975)
Other expense (income):				
Stated interest				

expense (income)	(8)	60	437	170
Imputed warrant interest expense, non-cash	85	44	3,894	44
Total other expense	\$77	\$104	\$4,331	\$214
Income (loss) before extraordinary item	\$830	(\$1,482)	(\$5,862)	(\$3,189)
Extraordinary loss			(256)	
Net income (loss)	\$830	(\$1,482)	(\$6,118)	(\$3,189)
PER SHARE DATA:				
Income (loss) before extraordinary item	\$0.10	(\$0.33)	(\$1.24)	(\$0.72)
Extraordinary loss			(0.06)	
Net income (loss) per share	\$0.10	(\$0.33)	(\$1.30)	(\$0.72)
Shares used in per share calculations	8,308	4,438	4,723	4,438

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

</TABLE>

EMCORE CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEET
(AMOUNTS IN THOUSANDS EXCEPT SHARE DATA)

<TABLE>

	AT JUNE 30, 1997 (UNAUDITED)	AT SEP. 30, 1996
ASSETS		
<S>	<C>	<C>
Cash and cash equivalents	\$7,709	\$1,367
Accounts receivable, net of allowance for doubtful accounts of \$315 and \$310 at June 30, 1997 and September 30, 1996, respectively	7,657	3,025
Inventories	6,980	7,645
Other current assets	145	79
Total current assets	\$22,491	\$12,116
Property and equipment, net	15,690	7,797
Other assets	463	521
Total assets	\$38,644	\$20,434
LIABILITIES		
CURRENT LIABILITIES:		
Accounts payable	\$4,905	\$5,661
Accrued expenses	2,670	1,987
Advanced billings	2,373	3,306
Other current liabilities	217	12
Total current liabilities	\$10,165	\$10,966
Subordinated debt	7,547	8,947
Total liabilities	\$17,712	\$19,913
STOCKHOLDERS' EQUITY:		
Common stock, no par value, 23,529,411 shares authorized, 5,921,190 shares issued and outstanding in 1997, 2,994,461 shares issued and outstanding in 1996	\$45,474	\$18,977
Accumulated deficit	(24,276)	(18,158)
Notes receivable from stock sales	(266)	(298)
Total stockholders' equity	\$20,932	\$521
Total liabilities and stockholders' equity	\$38,644	\$20,434

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

</TABLE>

EMCORE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(AMOUNTS IN THOUSANDS)
(Unaudited)

<TABLE>

	NINE MONTHS ENDED JUNE 30, 1997	1996
OPERATING ACTIVITIES:		
<S>	<C>	<C>
Net loss	(\$6,118)	(\$3,189)
Net loss		
Adjustments to reconcile net loss to		

net cash (used in) provided by operating activities:		
Depreciation and amortization	2,594	1,395
Provision for doubtful accounts	130	63
Detachable warrant accretion and valuation	3,892	35
Extraordinary loss on early debt extinguishment	256	
Provision for inventory valuation	30	69
Increase (decrease) in liabilities & (increase) decrease in assets:		
Accounts receivable	(4,762)	(978)
Inventories	635	(3,263)
Costs in excess of billings on uncompleted contracts	(7)	(16)
Billings in excess of costs on uncompleted contracts		222
Other current assets	(59)	16
Other assets	8	(198)
Accounts payable	(756)	1,870
Accrued expenses	683	241
Advanced billings	(933)	2,471
Other current liabilities	205	54
Total adjustments	\$1,916	\$1,981
Net cash used in operating activities	(\$4,202)	(\$1,208)

INVESTING ACTIVITIES:		
Purchase of property, plant, and equipment	(10,437)	(6,262)
Net cash used in investing activities	(\$10,437)	(\$6,262)

FINANCING ACTIVITIES:		
Proceeds from notes payable		2,000
Payments on notes payable and long-term debt		(5,000)
Proceeds from borrowings under demand note facility	8,000	
Proceeds from borrowings under subordinated notes		8,510
Payments on subordinated notes and demand note facility	(10,000)	
Net proceeds from initial public offering	22,765	
Net proceeds from stock options exercise	6	
Reduction in notes receivable from shareholders	210	
Net cash provided by financing activities	\$20,981	\$5,510
Net increase (decrease) in current cash	\$6,342	(\$1,960)
Current cash, beginning	1,367	2,323
Current cash, end of year	\$7,709	\$363

THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

</TABLE>

EMCORE CORPORATION
STATEMENT OF STOCKHOLDERS' EQUITY
BY QUARTER FROM SEPTEMBER 30, 1996, THROUGH JUNE 30, 1997
(AMOUNTS IN THOUSANDS)
(Unaudited)

<TABLE>

	COMMON STOCK		ACCUMULATED DEFICIT	SHAREHOLDERS'	TOTAL
	SHARES	AMOUNT		NOTES RECEIVABLE	SHAREHOLDERS' EQUITY
<S>	<C>	<C>	<C>	<C>	<C>
BALANCE AT SEPTEMBER 30, 1996	2,994	\$18,978	(\$18,158)	(\$298)	\$522
Issuance of common stock purchase warrants					
Net loss			(3,798)		(3,798)
BALANCE AT DECEMBER 31, 1996	2,994	\$22,578	(\$21,956)	(\$298)	\$324
Issuance of common stock from initial public					

offering, net of issuance costs of \$3,109	2,875	22,766			22,766
Cancellation of notes receivable due from shareholders				32	32
Net loss			(3,150)		(3,150)
BALANCE AT MARCH 31, 1997	5,869	\$45,344	(\$25,106)	(\$266)	\$19,972
Conversion of subordinated debt	31	124			124
Stock option exercise	21	6			6
Net income			830		830
BALANCE AT JUNE 30, 1997	5,921	\$45,474	(\$24,276)	(\$266)	\$20,932

</TABLE>

EMCORE CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Interim Financial Information The condensed consolidated financial statements of EMCORE Corporation (the "Company") are unaudited (except for the balance sheet information as of September 30, 1996 which is derived from the Company's audited financial statements) but reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position at June 30, 1997, and the operating results and cash flows for the quarters ended June 30, 1997, and June 30, 1996. The results of operations for the nine months ended June 30, 1997, are not necessarily indicative of the results for the entire fiscal year ending September 30, 1997, or any future interim period.

Cash and Cash Equivalents. The Company considers all highly liquid short-term investments purchased with an original maturity of three months or less to be cash equivalents. The Company had approximately \$4,891,000 and \$106,000 in cash equivalents at June 30, 1997, and September 30, 1996, respectively. As of June 30, 1997, the Company had restricted cash in the amount of \$375,000 due to contractual obligations.

Inventories. Inventories are stated at the lower of FIFO (first-in, first-out) cost or market. Reserves are established for slow moving or obsolete inventory based upon historical and anticipated usage.

Property and Equipment. Property and equipment are stated at cost. Significant renewals and betterments are capitalized. Maintenance and repairs that do not extend the useful lives of the respective assets are expensed.

Depreciation is recorded using the straight-line method over the estimated useful lives of the applicable assets, which range from three to five years. Leasehold improvements are amortized using the straight-line method over the term of the related leases or the estimated useful lives of the improvements, whichever is less.

When assets are retired or otherwise disposed of, the assets and related accumulated depreciation accounts are adjusted accordingly, and any resulting gain or loss is recorded in current operations.

In the event that facts and circumstance indicate that the value of assets may be impaired, an evaluation of recoverability is performed. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset would be compared to the assets carrying amount to determine if an adjustment to the carrying amount is required.

Deferred Costs. Included in other assets are deferred costs related to obtaining product patents. Such costs are being amortized over a five year period.

Income Taxes. The Company uses Statement of Financial Accounting Standards ("SFAS") No. 109, "Accounting for Income Taxes." SFAS No. 109 required a change from the deferred method to the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred income taxes are recognized for the tax consequences of "temporary differences" by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. Under SFAS No. 109, the effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. Under the deferred method, deferred taxes are recognized at the tax rate applicable to the year in which the difference between financial statement carrying amounts and the corresponding tax bases arose.

Revenue and Cost Recognition-Systems, Components and Service Revenues. Revenue from systems sales is recorded upon shipment to the customer. Subsequent to product shipment, the Company incurs certain installation costs at the customer's facility and warranty costs that are estimated and accrued at the time a sale is recorded.

Component sales and service revenues are recognized when goods are shipped or services are rendered to the customer. Service revenue under contracts with specified service terms is recognized as earned over the service period in accordance with the terms of the applicable contract. Costs in connection with the procurement of the contracts are charged to expense as incurred.

Revenue and Cost Recognition-Contract Revenue. The Company's research contracts require the development or evaluation of new materials' applications and have a duration of six to 36 months. For research contracts with the U.S. Government and commercial enterprises with a duration of greater than six months, the Company recognizes revenue to the extent of costs incurred plus the estimated gross profit as stipulated in such contracts, based upon contract performance.

Contracts with a duration of six months or less are accounted for on the completed contract method. A contract is considered complete when all costs, except insignificant items, have been incurred, and the research reporting requirements to the customer have been met.

Contract costs include all direct material and labor costs and those indirect costs related to contract performance, such as indirect labor, supplies, tools, repairs and depreciation costs, as well as coverage of certain general and administrative costs. Provisions for estimated losses on uncompleted contracts are made in the period in which such losses are determined.

Research and Development. Research and development costs related to the development of both present and future products and Company sponsored materials application research are charged to expense as incurred.

Fair Value of Financial Instruments. The Company estimates fair value based upon discounted cash flow analyses using the Company's incremental borrowing rate on similar instruments as the discount rate. As of June 30, 1997, the carrying values of the Company's cash and cash equivalents, receivables and accounts payable recorded on the accompanying balance sheets approximate fair value.

Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.

The Company's most significant estimates relate to accounts receivable and inventory valuation reserves, warranty and installation reserves, estimates of cost and related gross profits on certain research contracts and the valuation of long-lived assets.

New Accounting Standards.. In March 1995, the Financial Accounting Standards Board ("FASB") issued SFAS No. 121, "Accounting for the Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed Of" ("SFAS No. 121"). This pronouncement establishes accounting standards for when impairment losses relating to long-lived assets, identifiable intangibles and goodwill related to those assets should be recognized and how the losses should be measured. The Company plans to implement SFAS No. 121 in fiscal 1997. The adoption of SFAS No. 121 is not expected to have an impact on the Company's financial position or results of operations since EMCORE's current policy is to monitor assets for impairment and record any necessary write-downs.

In October 1995, the FASB issued SFAS No. 123, "Accounting for Stock Based Compensation" ("SFAS No. 123"). The provision of SFAS No. 123 sets forth the method of accounting for stock based compensation based on the fair value of stock options and similar instruments, but does not require the adoption of this preferred method. SFAS No. 123 also requires the disclosure of additional information about stock compensation plans, even if the preferred method of accounting is not adopted. The Company plans to implement SFAS No. 123 in fiscal 1997. The Company does not intend to change its method of accounting for stock based compensation to the preferred method under SFAS No. 123, but instead will continue to apply the provisions of No. 25 "Accounting for Stock Issued to Employees." However, the Company will disclose the pro forma effect of SFAS No. 123 on net income and earnings per share.

In February 1997, the FASB issued SFAS No. 128, "Earnings per Share" ("SFAS No. 128"). SFAS No. 128 establishes standards for computing and presenting earnings per share ("EPS") for periods ending after December 15, 1997. SFAS No. 128 is designed to improve EPS information provided in financial statements by simplifying the existing computational guidelines, revising disclosure requirements, and increasing the comparability of EPS on an international basis. Basic and diluted earnings per share, calculated pursuant to SFAS No. 128, are not expected to be materially different from net

income per common share as reflected in the accompanying Condensed Consolidated Statements of Income.

NOTE 2. DEBT

On March 31, 1997, the Company entered into a new \$10.0 million revolving loan and security agreement (the "Agreement") with First Union National Bank. The Agreement bears interest at the rate of First Union's prime rate plus 50 basis points and has a revolving loan maturity date of and expires on September 30, 1998. There are presently no borrowings outstanding under the Agreement.

NOTE 3. INVENTORIES

Inventories comprise (in thousands):	AT	
	JUNE 30, 1997	SEPTEMBER 30, 1997
Raw Materials	\$5,619	\$4,965
Work-in-progress	1,361	2,680
Finished goods		
Total	\$6,980	\$7,645

ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

The Company was founded in 1986 and is a designer and developer of compound semiconductor materials and process technology and a manufacturer of production systems used to fabricate compound semiconductor wafers. Compound semiconductors are used in a broad range of applications in wireless communications, telecommunications, computers, and consumer and automotive electronics. The Company has recently capitalized on its technology base by expanding into the design and production of compound semiconductor wafers and package-ready devices. The Company offers its customers a complete, vertically-integrated solution for the design, development and production of compound semiconductor wafers and devices.

RESULTS OF OPERATIONS:

REVENUES

The Company's third quarter revenues increased 83% from \$7.7 million for the quarter ended June 30, 1996, to \$14.1 million for the quarter ended June 30, 1997. Revenues for the first nine months of fiscal 1997 increased 98% from \$18.0 million for the nine months ended June 30, 1996, to \$35.6 million for the nine months ended June 30, 1997. The revenue increase in each of the three and nine month periods was primarily attributable to increased demand for MOCVD (metal-organic chemical vapor deposition) systems and package-ready devices, as well as the introduction of compound semiconductor wafer products and contract and licensing activities. International sales accounted for approximately 46% and 58% of revenues for the nine months ended June 30, 1997 and 1996, respectively.

The Company believes that in the future its revenues and results of operations in a quarterly period could be impacted by the timing of customer development projects and related purchase orders for the Company's varied products, new merchandise announcements and releases by the Company, and economic conditions generally and the compound semiconductor industry environment specifically.

COST OF SALES/GROSS PROFIT

Cost of sales includes direct material and labor costs, allocated manufacturing and service overhead, and installation and warranty costs. Gross profit increased from 29% of revenue for the quarter ended June 30, 1996, to 42% of revenue for the quarter ended June 30, 1997. For the nine months ended June 30, gross profit increased from 32% to 33% for 1996 and 1997, respectively. The gross profit percentage increase was attributable to margins on wafer and device revenue and contract and licensing activities.

SELLING, GENERAL, AND ADMINISTRATIVE

Selling, general, and administrative expenses increased by 35% from \$1.9 million for the quarter ended June 30, 1996, to \$2.6 million in the quarter ended June 30, 1997. For the first nine months of fiscal year 1997, selling, general, and administrative expenses increased by 35% from \$5.0 million for the nine months ended June 30, 1996, to \$6.7 million for the nine months ended June 30, 1997. The increase in each of the three and nine month periods was largely due to sales personnel headcount increases to support both domestic and foreign markets and general headcount additions to sustain the internal administrative support necessary for the Company's increased business as well as higher expenses attributable to increased revenues. However, as a percentage of revenue, selling, general, and administrative expenses decreased from 25% for the third quarter of the prior year to 18% for the third quarter of the current year. For the nine months ended June 30, selling, general, and administrative expenses decreased from 28% of revenue for the prior year to 19% of revenue for the current year.

RESEARCH AND DEVELOPMENT

Research and development expenses increased by 42% from \$1.7 million in the quarter ended June 30, 1996, to \$2.4 million in the quarter ended June 30, 1997. For the first nine months of fiscal year 1997, research and development expenses increased by 80% from \$3.7 million for the nine months ended June 30, 1996, to \$6.7 million for the nine months ended June 30, 1997. The increase was primarily attributable to increased staffing and equipment costs necessary to enhance current products and research and development activities for the initiation of the Company's two new product lines (epitaxial wafers and package-ready devices). However, as a percentage of revenue, research and development expenses decreased from 22% for the third quarter of 1996 to 17% for the third quarter of 1997. For the nine months ended June 30, research and development expenses decreased from 21% of revenue for the prior year to 19% of revenue for the current year. To maintain growth and market leadership in epitaxial technology, the Company expects to continue to invest a significant amount of its resources in research and development.

OPERATING INCOME (LOSS)

Operating profit increased \$2.3 million from a loss of \$1.4 million in the quarter ended June 30, 1996, to a profit of \$0.9 million in the quarter ended June 30, 1997. For the first nine months of fiscal year 1997, operating loss decreased \$1.4 million from a loss of \$2.9 million for the nine months ended June 30, 1997. These changes in operating income (loss) are primarily due to higher revenues generating a greater overall gross profit.

OTHER EXPENSE

During fiscal 1996, the Company issued detachable warrants along with subordinated notes to certain of its existing shareholders. In the first quarter of fiscal year 1997, the Company also issued detachable warrants in return for a \$10.0 million demand note facility (the "Facility") guarantee by a director of the Company, affiliated with the Company's majority shareholder, who provided collateral for the Facility. The Company subsequently assigned a value to these detachable warrants' issues using a commonly recognized option pricing model, the Black-Scholes Option Pricing Model. The Company recorded the subordinated notes at a carrying value that is subject to periodic accretions, using the interest method, and reflected the Facility detachable warrant value as a debt issuance cost. The consequent expense of these warrant accretion amounts and the now terminated Facility debt issuance cost is charged to "Imputed warrant interest, non-cash," and amounted to \$44,000 and \$3.9 million for the quarter and nine months ended June 30, 1997, respectively.

Borrowings under the Company's \$10.0 million demand note facility with First Union National Bank totaling \$8.0 million were utilized to fund capital expenditures in connection with the build-out of the Company's manufacturing facility during the six months ended March 31, 1997. The resultant interest expense was the primary reason for the increase in "Stated interest expense" for the nine months ended June 30, 1997. The outstanding \$8.0 million under this demand note facility was repaid in March 1997, resulting in much lower interest expense for the quarter ended June 30, 1997.

EXTRAORDINARY ITEM

The Company repaid \$10.0 million of its outstanding debt with proceeds from its IPO. The entire \$8.0 million outstanding of its demand note facility with First Union National Bank was repaid and \$2.0 million was used to repay a portion of the Company's outstanding subordinated notes due May 1, 2001. In connection with the discharge of the Company's subordinated notes, an extraordinary loss of \$256,000 was recognized.

NET INCOME/LOSS

Net income increased \$2.3 million from a loss of \$1.5 million to income of \$0.8 million for the quarters ended June 30, 1996, and 1997, respectively. For the nine months ended, the Company's net loss increased \$2.9 million from \$3.2 million for the nine months ended June 30, 1996, to \$6.1 million for the nine months ended June 30, 1997. This year-to-date increase was primarily attributable to the aforementioned \$3.9 million of debt issuance cost amortization related to warrants.

BACKLOG

The Company's order backlog decreased 1% from \$23.0 million as of June 30, 1996, to \$22.7 million as of June 30, 1997. The Company includes in backlog only customer purchase orders which have been accepted by the Company and for which shipment dates have been assigned within the twelve months to follow and research contracts that are in process or awarded. Wafer and device contract agreements extending longer than one year in duration are included in backlog only for the ensuing 12 months and 3 months, respectively. Some of these agreements currently extend over five years. The Company receives partial advance payments or irrevocable letters of credit on most production system orders and has never experienced an order cancellation. Although the Company has increased its capacity to meet continued increased production needs, there can be no assurance that the Company will be consistently able to increase its capacity to meet its scheduled needs.

Liquidity And Capital Resources

Cash and cash equivalents increased by \$6.3 million from \$1.4 million at

September 30, 1996, to \$7.7 million at June 30, 1997. For the nine months ended June 30, 1997, net cash used by operations amounted to \$4.2 million, primarily due to the Company's net losses, increase in accounts receivable, decrease in accounts payable and advanced billings, offset by the Company's non-cash items, including depreciation, amortization, and detachable warrant accretion and valuation. For the nine months ended June 30, 1997, net cash used in investment activities amounted to \$10.4 million due to purchase and manufacture of new equipment for the Company's wafer and package ready device product lines and to new facility clean room modifications and enhancements. For the nine months ended June 30, 1997, net cash from financing activities, primarily including the \$22.8 million IPO proceeds, accounted for the majority of the resulting net cash increase.

On March 31, 1997, the Company entered into a \$10.0 million revolving loan and security agreement (the "Agreement") with First Union National Bank. The Agreement bears interest at the rate of First Union's prime rate plus 50 basis points and has a revolving loan maturity date of and expires on September 30, 1998. There are presently no borrowings under the Agreement.

The Company believes that its current liquidity, together with the Agreement, will be sufficient to meet its cash needs for working capital and capital expenditures through fiscal 1997. Thereafter, if cash generated from operations is insufficient to satisfy the Company's liquidity requirements, the Company may be required to raise funds through equity or debt offerings or obtain additional credit facilities if possible. Additional funding may not be available when needed or on terms acceptable to the Company, which could have a material adverse effect on the Company's business or financial condition or operations.

Certain statements which are not historical facts in this report may be forward-looking statements and are based on assumptions the Company believes are reasonable. Such forward-looking statements may include business forecasts, financial projections, or statements concerning the Company's expectations for demand and sales of new or existing products, industry and market segment growth, market and technology opportunities, development of processes, the commencement of production, or the future financial performance of the Company. Such forward-looking statements involve risks and uncertainties. Actual operating results may differ materially from projections or forecasts contained in forward-looking statements and are subject to certain risks including, without limitation, risks in developing and commercializing new products, and other factors described in the Company's filings with the Securities and Exchange Commission.

PART II OTHER INFORMATION

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) List of Exhibits:

- 11 Statement re: computation of per share earnings for the nine months ended June 30, 1997.
- 27 Financial Data Schedule

(b) No reports on Form 8-K were filed during the quarter ended June 30, 1997. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

EMCORE CORPORATION

DATE: August 14, 1997 By: /s/ Reuben F. Richards, Jr.
Reuben F. Richards, Jr.
President and Chief Executive
Officer

DATE: August 14, 1997 By: /s/ Thomas G. Werthan
Thomas G. Werthan
Vice President, Finance and Administration
EXHIBIT INDEX

EXHIBIT	DESCRIPTION
---------	-------------

11	Statement re: computation of per share earnings for the nine months ended June 30, 1997.
27	Financial Data Schedule

EMCORE CORPORATION
 STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS
 (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
 (Unaudited)

<TABLE>

	THREE MONTHS		NINE MONTHS	
	ENDED JUNE 30,		ENDED JUNE 30,	
	1997	1996	1997	1996
<S>	<C>	<C>	<C>	<C>
Income (loss) before extraordinary item	\$830	(\$1,482)	(\$5,862)	(\$3,189)
Extraordinary loss			(256)	
Net income (loss)	\$830	(\$1,482)	(\$6,118)	(\$3,189)
Primary earnings per share calculation:				
Weighted average shares outstanding:				
Common stock	5,915	2,994	4,242	2,994
Common stock equivalents(1)	2,393	1,444	481	1,444
Primary weighted average common shares and equivalents	8,308	4,438	4,723	4,438
Income (loss) before extraordinary item	\$0.10	(\$0.33)	(\$1.24)	(\$0.72)
Extraordinary loss			(0.06)	
Net income (loss) per share	\$0.10	(\$0.33)	(\$1.30)	(\$.72)
Fully diluted earnings per share calculation:(2)				
Weighted average shares outstanding:				
Common stock	5,915	2,994	4,242	2,994
Common stock equivalents(1)	2,587	1,444	481	1,444
Fully-diluted weighted average common shares and equivalents	8,502	4,438	4,723	4,438
Income (loss) before extraordinary item	\$0.10	(\$0.33)	(\$1.24)	(\$0.72)
Extraordinary loss			(0.06)	
Net income (loss) per share	\$0.10	(\$0.33)	(\$1.30)	(\$.72)

</TABLE>

- (1) Under the provisions of Securities and Exchange Commission Staff Bulletin No. 64 ("SAB" No. 64), common stock and common stock equivalents issued by the company within one year or in contemplation of the Company's offering are treated as if they were outstanding for all periods presented prior to the Company's IPO. After the IPO is effective, the determination of common stock and equivalents has been determined on a basis consistent with APB Opinion No. 15, which states "outstanding options and warrants should be included in the EPS computation only if they have a dilutive effect."
- (2) This calculation is submitted in accordance with Securities Exchange Act of 1934 Release No. 9083 although not required by footnote 2 of paragraph 14 of APB Opinion No. 15 because it results in dilution of less than 3%.

<TABLE> <S> <C>

<ARTICLE> 5

<LEGEND>

Note: This schedule contains summary financial information extracted from the Consolidated Financial Statements of Emcore Corporation for the quarterly period ended June 30, 1997, and is qualified in its entirety by reference to such financial statements.

</LEGEND>

<S>	<C>
<PERIOD-TYPE>	9-MOS
<FISCAL-YEAR-END>	SEP-30-1997
<PERIOD-END>	JUN-30-1997
<CASH>	7,709
<SECURITIES>	0
<RECEIVABLES>	7,972
<ALLOWANCES>	315
<INVENTORY>	6,980
<CURRENT-ASSETS>	22,491
<PP&E>	25,915
<DEPRECIATION>	10,225
<TOTAL-ASSETS>	38,644
<CURRENT-LIABILITIES>	10,165
<BONDS>	0
<PREFERRED-MANDATORY>	0
<PREFERRED>	0
<COMMON>	45,474
<OTHER-SE>	24,542
<TOTAL-LIABILITY-AND-EQUITY>	38,644
<SALES>	35,626
<TOTAL-REVENUES>	35,626
<CGS>	23,787
<TOTAL-COSTS>	23,787
<OTHER-EXPENSES>	13,370
<LOSS-PROVISION>	0
<INTEREST-EXPENSE>	4,331
<INCOME-PRETAX>	(5,862)
<INCOME-TAX>	0
<INCOME-CONTINUING>	(5,862)
<DISCONTINUED>	0
<EXTRAORDINARY>	(256)
<CHANGES>	0
<NET-INCOME>	(6,118)
<EPS-PRIMARY>	(1.30)
<EPS-DILUTED>	(1.30)

</TABLE>